Pregabalin for the management of partial epilepsy

Philippe Ryvlin, Emilio Perucca, Sylvain Rheims

Research output: Contribution to journalArticlepeer-review


Pregabalin is one of the latest antiepileptic drugs introduced for the treatment of partial epilepsy. Its efficacy and safety as adjunctive therapy in refractory partial epilepsy have been established in four double-blind placebo-controlled trials (n = 1396) and 4 long-term open-label studies (n = 1480). In 3 fixed-dose trials, the proportion of patients with a ≥50% reduction in seizure frequency across the effective dose-range (150-500 mg/day) ranged between 14% and 51%, with a clear dose-response relationship. Suppression of seizure activity could be demonstrated as early as day 2. The most frequently reported CNS-related adverse events included dizziness, somnolence, ataxia and fatigue, were usually mild or moderate, and tended to be dose related. In long-term studies, weight gain was reported as an adverse event by 24% of patients. When pregabalin dose was individualized to according to response within the 150 to 600 mg/day dose range, tolerability was considerably improved compared with use of a high-dose, fixed-dose regimen (600 mg/day) without titration. In long-term studies up to 4 years, no evidence of loss efficacy was identified. During the last year on pregabalin, 3.7% of patients were seizure-free. Pregabalin appears to be a useful addition to the therapeutic armamentariun for the management of refractory partial epilepsy.

Original languageEnglish
Pages (from-to)1211-1224
Number of pages14
JournalNeuropsychiatric Disease and Treatment
Issue number6
Publication statusPublished - 2008


  • Adjunctive therapy
  • Antiepileptic drugs
  • Clinical trials
  • Efficacy
  • Partial seizures
  • Pregabalin
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Pregabalin for the management of partial epilepsy'. Together they form a unique fingerprint.

Cite this